CRSP FY2024 EPS Lifted by Brookline Capital Management

CRISPR Therapeutics AG (NASDAQ:CRSP) – Brookline Capital Management raised their FY2024 earnings per share (EPS) estimates for shares of CRISPR Therapeutics in a research report issued to clients and investors on Monday, January 6th. Brookline Capital Management analyst L. Cann now anticipates that the company will earn ($5.16) per share for the year, up from their prior forecast of ($5.18). The consensus estimate for CRISPR Therapeutics’ current full-year earnings is ($5.13) per share.

CRSP has been the subject of several other reports. Royal Bank of Canada reissued a “sector perform” rating and set a $53.00 price target on shares of CRISPR Therapeutics in a research report on Wednesday, November 6th. StockNews.com raised CRISPR Therapeutics to a “sell” rating in a report on Monday, December 30th. Bank of America lowered their target price on shares of CRISPR Therapeutics from $98.00 to $85.00 and set a “buy” rating on the stock in a report on Tuesday. JMP Securities reiterated a “market outperform” rating and issued a $86.00 price target on shares of CRISPR Therapeutics in a research note on Friday, December 20th. Finally, Needham & Company LLC restated a “buy” rating and set a $84.00 price objective on shares of CRISPR Therapeutics in a research note on Wednesday, November 6th. Two analysts have rated the stock with a sell rating, eight have given a hold rating and ten have assigned a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $78.38.

CRISPR Therapeutics Price Performance

CRISPR Therapeutics stock opened at $41.29 on Thursday. The firm has a 50-day moving average of $46.50 and a 200-day moving average of $48.88. The company has a market cap of $3.52 billion, a price-to-earnings ratio of -14.59 and a beta of 1.68. CRISPR Therapeutics has a one year low of $38.20 and a one year high of $91.10.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its earnings results on Tuesday, November 5th. The company reported ($1.01) EPS for the quarter, topping the consensus estimate of ($1.42) by $0.41. CRISPR Therapeutics had a negative net margin of 118.13% and a negative return on equity of 12.15%. The business had revenue of $0.60 million during the quarter, compared to analysts’ expectations of $6.65 million. During the same quarter in the prior year, the company posted ($1.41) earnings per share.

Insider Activity

In related news, General Counsel James R. Kasinger sold 1,089 shares of the business’s stock in a transaction that occurred on Monday, October 14th. The stock was sold at an average price of $46.28, for a total value of $50,398.92. Following the completion of the sale, the general counsel now directly owns 62,597 shares in the company, valued at approximately $2,896,989.16. The trade was a 1.71 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Samarth Kulkarni sold 30,000 shares of the stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $55.62, for a total value of $1,668,600.00. Following the sale, the chief executive officer now directly owns 196,540 shares in the company, valued at $10,931,554.80. This represents a 13.24 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 50,382 shares of company stock valued at $2,744,179. 4.10% of the stock is owned by company insiders.

Institutional Investors Weigh In On CRISPR Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of CRSP. Itau Unibanco Holding S.A. bought a new position in CRISPR Therapeutics in the 2nd quarter valued at about $35,000. National Bank of Canada FI increased its stake in CRISPR Therapeutics by 35.0% in the second quarter. National Bank of Canada FI now owns 848 shares of the company’s stock valued at $46,000 after acquiring an additional 220 shares during the last quarter. Wilmington Savings Fund Society FSB acquired a new position in CRISPR Therapeutics during the third quarter valued at approximately $40,000. Darwin Wealth Management LLC bought a new stake in CRISPR Therapeutics during the third quarter worth $43,000. Finally, Elkhorn Partners Limited Partnership acquired a new stake in shares of CRISPR Therapeutics in the 2nd quarter valued at $54,000. Institutional investors own 69.20% of the company’s stock.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.